NCT03972488 2026-01-21NETTER-2Advanced Accelerator ApplicationsPhase 3 Active not recruiting226 enrolled 14 charts
NCT01578239 2022-04-04NETTER-1Advanced Accelerator ApplicationsPhase 3 Completed231 enrolled 16 charts 2 FDA
NCT01789281 2021-06-11Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.NovartisPhase 4 Completed34 enrolled 8 charts
NCT00781911 2019-09-20A Study of Cixutumumab (IMC-A12) in Islet Cell CancerEli Lilly and CompanyPhase 2 Completed43 enrolled 12 charts